Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PainChek (PCK) has accelerated its growth within the U.K. market after receiving its first order for aged care beds
  • Following a number of successful trials, Person Centred Software U.K. has placed an order for 1000 PainChek annual bed licences
  • This is the first direct sale made by PainChek U.K. to a dementia-specific aged care centre
  • PainChek is currently up 4.76 per cent with shares trading for 22 cents apiece

PainChek (PCK) has accelerated its growth within the U.K. market after receiving its first order for aged care beds.

Following a number of successful trials within Aged Care, Person Centred Software U.K. (PCS U.K.) have placed an order for 1000 PainChek annual bed licences as an initial supply for their U.K. aged care and nursing home clients.

“We have more than 55,000 resident beds under PCS licenses in the U.K. across more than 1500 aged care homes,” PCS UK Founder and Director Johnathan Papworth commented.

“We have received very positive feedback on the PainChek system from our trial sites and our sales teams are actively marketing the combined PCS and PainChek package to our existing and new client base,” he added.

The U.K. has 540,000 residential aged care beds across 18,000 homes with 82 per cent of the homes privately owned, 15 per cent run by voluntary organisations and 3 per cent managed by local councils.

Around 40 per cent of residential aged care is self-funded, 49 per cent receive Council funding and 10 per cent is NHS (national health service) funded.

This collaboration with PCS provides immediate access to 1500 homes but more importantly, a significantly higher proportion of those that have adopted care planning technology.

The software integration between PainChek and PCS provides a clear and mutual benefit to both organisations across both the U.K. and Australia.

PainChek is a fast and simple solution that uses the smartphone camera to record a short video of the person’s face and then analyses it using facial recognition analytics.

It automatically recognises facial muscle movements that indicate pain and takes note of them.

The caregiver then uses PainChek to record observations of pain-related behaviours such as how the person is moving and vocalising pain.

PainChek then calculates an overall pain score and stores the results allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek U.K. has also teamed up with an Outstanding Care Quality Commission (CQC) rated dementia focussed care home based near Manchester.

This is part of PainChek’s direct selling to aged care program and the CQC rating is the highest rating a home can achieve as an aged care facility in the U.K.

PainChek is currently up 4.76 per cent with shares trading for 22 cents apiece at 1:14 pm AEDT.

PCK by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.